VTGN · NASDAQ
Vistagen Therapeutics (VTGN) Stock Price & Fundamentals
Vistagen Therapeutics (VTGN) closed at $975.68 on Oct 9, 2026, down 1.03% from the previous close of $985.80.
Share price, past year
1Y +36.83%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $975.68 |
| Sep 30, 2026 | $976.40 |
| Aug 31, 2026 | $884.14 |
| Jul 31, 2026 | $876.67 |
| Jun 30, 2026 | $877.53 |
| May 29, 2026 | $813.29 |
| Apr 30, 2026 | $807.14 |
| Mar 31, 2026 | $831.99 |
| Feb 27, 2026 | $801.43 |
| Jan 30, 2026 | $828.61 |
| Dec 31, 2025 | $729.98 |
| Nov 28, 2025 | $729.20 |
| Oct 31, 2025 | $711.35 |
Key statistics
- Market cap
- $40.03B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.66
- Revenue (TTM)
- $2.50M
- Net income (TTM)
- −$67.62M
- Shares outstanding
- 41M
- Dividend yield
- —
- 52-week range
- $692.08 – $1,000.07
Vistagen Therapeutics's market cap is $40.03B, based on a share price of $975.68 and 41M shares outstanding as of Jun 12, 2026.
Financials
Vistagen Therapeutics reported revenue of $1.27M for fiscal 2026, up 161.11% from fiscal 2025.
Vistagen Therapeutics reported a net loss of $69.69M in fiscal 2026.
Fiscal 2026 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended Mar 31, 2026 | $1.27M | +161.1% | −$69.69M | −5,491.3% | −$1.83 | — |
| FY2025ended Mar 31, 2025 | $486.00K | −54.3% | −$51.42M | −10,579.8% | −$1.67 | — |
| FY2024ended Mar 31, 2024 | $1.06M | +568.7% | −$29.36M | −2,759.6% | −$1.52 | — |
| FY2023ended Mar 31, 2023 | −$227.00K | −120.5% | −$59.25M | 26,100.4% | −$8.51 | — |
| FY2022ended Mar 31, 2022 | $1.11M | +1.8% | −$47.76M | −4,306.8% | — | −$45.46M |
| FY2021ended Mar 31, 2021 | $1.09M | — | −$17.93M | −1,646.1% | −$14.71 | −$12.35M |
| FY2020ended Mar 31, 2020 | $0.00 | — | −$20.77M | — | −$15.02 | −$15.76M |
| FY2018ended Mar 31, 2018 | $0.00 | −100.0% | −$14.35M | — | −$33.63 | −$9.06M |
| FY2017ended Mar 31, 2017 | $1.25M | — | −$10.26M | −820.4% | −$46.25 | — |
| FY2016ended Mar 31, 2016 | $0.00 | — | — | — | −$873.27 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2027ended Jun 30, 2026 | $1.48M | −$13.03M | −$0.30 |
| Q4 FY2026ended Mar 31, 2026 | $464.00K | −$16.27M | −$0.37 |
| Q3 FY2026ended Dec 31, 2025 | $303.00K | −$18.90M | −$0.45 |
| Q2 FY2026ended Sep 30, 2025 | $258.00K | −$19.42M | −$0.54 |
| Q1 FY2026ended Jun 30, 2025 | $244.00K | −$15.10M | −$0.47 |
| Q3 FY2025ended Dec 31, 2024 | $234.00K | −$14.09M | −$0.46 |
| Q2 FY2025ended Sep 30, 2024 | $183.00K | −$12.96M | −$0.42 |
| Q1 FY2025ended Jun 30, 2024 | $84.00K | — | — |
Company profile
- Name
- Vistagen Therapeutics, Inc.
- Ticker
- VTGN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 343 Allerton Avenue, South San Francisco, CA 94080
- Incorporated in
- NV
- Fiscal year ends
- March
- SEC CIK
- 0001411685
Recent SEC filings
- Sep 25, 2026
- Sep 24, 2026
- Sep 22, 2026
- Sep 11, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 6, 2026
- Aug 5, 2026
Frequently asked questions
What is Vistagen Therapeutics's stock price?
Vistagen Therapeutics (VTGN) closed at $975.68 on Oct 9, 2026, down 1.03% from the previous close of $985.80.
What is Vistagen Therapeutics's market cap?
Vistagen Therapeutics's market cap is $40.03B, based on a share price of $975.68 and 41M shares outstanding as of Jun 12, 2026.
How much revenue does Vistagen Therapeutics make?
Vistagen Therapeutics reported revenue of $1.27M for fiscal 2026, up 161.11% from fiscal 2025.
Does Vistagen Therapeutics pay a dividend?
Vistagen Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Vistagen Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures